Valuation: Actinium Pharmaceuticals, Inc.

Market Cap 37.73M 33.66M 31.36M 28.54M 53.74M 3.63B 54.14M 379M 147M 1.85B 142M 139M 5.96B P/E 2026 *
6.79x
P/E 2027 * -1.79x
Enterprise Value 37.73M 33.66M 31.36M 28.54M 53.74M 3.63B 54.14M 379M 147M 1.85B 142M 139M 5.96B EV / Sales 2026 *
2.16x
EV / Sales 2027 * -
Free-Float
91.92%
Yield 2026 *
-
Yield 2027 * -
08-15 Actinium Pharmaceuticals Expands Manufacturing Capacity for Actimab-A Program CI
08-15 Actinium Pharmaceuticals, Inc. Amends Its Investigational New Drug CI
08-08 Actinium Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
06-03 Actinium Pharmaceuticals Presents New Data on Atnm-400 Demonstrating Potent Activity in Prostate Cancer Models Resistant to All Three Approved Androgen Receptor Inhibitors CI
06-01 Actinium Pharmaceuticals, Inc. Appoints Steffen Heeger as Chief Medical Officer CI
06-01 Actinium Pharmaceuticals Presents New Radiochemistry Data Demonstrating That CAR Optimization Improves Tumor Targeting and Pharmacokinetics of Actinium-225 Radioconjugates CI
05-30 Actinium Pharmaceuticals - receives two Canadian patent allowances for Actimab-A and Iomab-Act programs RE
05-30 Actinium Pharmaceuticals Receives Patent Allowances for Actimab-A and Iomab-Act Programs in Canada CI
05-09 Actinium Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
05-06 Actinium Pharmaceuticals Announces Three SNMMI 2026 Presentations Highlighting Differentiated Profile of Atnm-400 Across Lung and Prostate Cancer and Radioconjugate Optimization CI
04-22 Actinium Pharmaceuticals, Inc. Highlights Transcriptional Reprogramming As Key Mechanism Underpinning Mutation-Agnostic Activity Of Actimab-A In AML CI
04-22 Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models At the 2026 American Association of Cancer Research Annual Meeting CI
04-06 Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for Atnm-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in Aml CI
1 day+2.56%
1 week+1.69%
Current month+7.14%
1 month+16.50%
3 months+22.32%
6 months+22.40%
Current year-11.76%
1 week 1.1
Extreme 1.1
1.24
1 month 1.06
Extreme 1.06
1.42
Current year 0.74
Extreme 0.735101
1.53
1 year 0.74
Extreme 0.735101
1.74
3 years 0.74
Extreme 0.735101
10.24
5 years 0.74
Extreme 0.735101
15.12
10 years 0.74
Extreme 0.735101
51.6
Manager TitleAgeSince
Chief Executive Officer 62 09/06/2017
Chief Tech/Sci/R&D Officer - 01/06/2026
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 71 01/01/2008
Chairman 62 01/10/2013
Director/Board Member 68 08/11/2013
Date Insider Type Main position Quantity % Market Cap. Importance
9/3/26 A Other

Chief Technology Officer

333,648 1.0634%
9/3/26 A Other

Chief Technology Officer

403,868 1.2872%
9/2/26 A Free

Director

157,000 0.5004%
Change 5-day change 1-year change 3-year change Capi.($)
+2.56%+1.69%-24.05%-80.26% 37.73M
+4.16%+3.42%+49.37%+94.17% 74.31B
+0.62%-3.47%+20.48%+75.15% 56.95B
+2.30%+1.03%+5.89%+37.53% 48.3B
-1.07%+2.94%+344.62%+722.17% 44.51B
+2.36%-1.80%+28.78%+34.51% 43.8B
+0.90%-1.46%+5.17%+111.90% 41.12B
-0.54%+2.41%+9.31%+58.85% 31.07B
+4.51%+8.22%+37.86%+32.49% 28.97B
+1.83%-1.45%-7.44%-11.12% 24.53B
Average +1.86%-0.39%+47.00%+107.54% 39.36B
Weighted average by Cap. +1.91%-0.46%+58.78%+136.80%

Financials

2026 *2027 *
Net sales 17.5M 15.61M 14.54M 13.24M 24.93M 1.69B 25.11M 176M 68.38M 860M 65.69M 64.28M 2.76B -
Net income 5.91M 5.27M 4.91M 4.47M 8.42M 569M 8.48M 59.37M 23.1M 291M 22.19M 21.71M 934M -30.95M -27.61M -25.72M -23.41M -44.08M -2.98B -44.41M -311M -121M -1.52B -116M -114M -4.89B
Net Debt - -
Logo Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company pioneering the development of targeted radiotherapies to address significant unmet medical needs in oncology. It operates a pipeline of both early and later stage development programs with two novel solid tumor product candidates, ATNM-400 and Actimab-A, with pan-tumor potential; Actimab-A, which is also being developed as a therapeutic backbone for acute myeloid leukemia and myelodysplastic syndrome in partnership with the National Cancer Institute (NCI), and two targeted conditioning agents, Iomab-B for bone marrow transplant and Iomab-ACT for cell & gene therapies. Its solid tumor asset, ATNM-400, targets a novel antigen distinct from PSMA, with demonstrated preclinical activity across metastatic castration-resistant prostate cancer (mCRPC), non-small cell lung cancer (NSCLC), and breast cancer. Its hematology franchise includes Actimab-A, Iomab-B and Iomab-ACT, which are CD45-targeting conditioning agents.
Employees
27
Date Price Change Volume
05/10/26 $1.200 +2.56% 115,026
02/10/26 $1.170 +1.74% 81,800
01/10/26 $1.150 +2.68% 90,832
30/09/26 $1.120 -1.75% 95,130
29/09/26 $1.140 -3.39% 62,022
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.200USD
Average target price
3.600USD
Spread / Average Target
+200.00%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ATNM Stock